| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.06 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.07 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.07 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.07 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.08 |